Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase InhibitorMaria Gabriella Brasca, Marina Ciomei, Nadia Amboldi et al.|Journal of Medicinal Chemistry|2009Cited by 128
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Wilma Pastori et al.|Molecular Cancer Therapeutics|2010Cited by 63
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21
Optimization of Diarylthiazole B‐Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical EffectMaurizio Pulici, Marina Ciomei, Gabriella Traquandi et al.|ChemMedChem|2014Cited by 9
294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125Rachele Alzani, C. Mercurio, Clara Albanese et al.|European Journal of Cancer Supplements|2008Cited by 1